Herpes Zoster

Skin

Shingles

Herpes zoster (shingles) is caused by reactivation of the varicella-zoster virus, which remains dormant in nerve roots after childhood chickenpox. It presents as a painful, blistering rash limited to one side of the body, following a dermatomal pattern. Symptoms often begin with burning, tingling, or localized pain, followed by a red rash that develops into fluid-filled blisters.

The rash typically resolves in 2–4 weeks, but some people, especially older adults, may develop postherpetic neuralgia—persistent nerve pain lasting weeks to months. Risk increases with age or immune suppression. Antiviral medications (e.g., valacyclovir, acyclovir) started early can reduce symptom severity and duration. Shingrix, a recombinant zoster vaccine, is recommended for adults over 50 to reduce the risk of shingles and its complications.

AI Summary of Treatment Experiences

Not medical advice.

The treatment landscape for Herpes Zoster (shingles) involves both preventive and acute management strategies. Shingrix, a highly effective vaccine, is recommended for adults 50 and older to reduce the risk of shingles and postherpetic neuralgia by over 90%. For active shingles cases, antiviral medications like valacyclovir, famciclovir, and acyclovir are first-line treatments, with valacyclovir being preferred due to its convenient dosing and effectiveness in reducing rash duration, pain severity, and the risk of complications. Pain management is also an important symptomatic treatment for shingles, as the condition can cause significant discomfort.